EVFM - Earnings call transcript Q2 2022 | Evofem Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon.

Now, I'll turn the call over to Amy Raskopf, Evofem Biosciences' Vice President of Investor Relations. Please go ahead.

Amy Raskopf

Thank you, Larry. Good afternoon, everyone, and welcome to the Evofem Biosciences’ results call for the second quarter of 2022.

both so accompanies encourage press the this issued market done the to release Investors haven't be after that may presentation call close, tab. you already, evofem.com you I access we found If at which under of and the

on are XXXX. Before begin, made of August X, made only like will contain you that to as we call remind forward-looking would remarks I this statements, which today,

other results most that of This For involves differ that, a on call to estimates. data of Evofem's about description company I'll and refer statistical cause by the parties our materially, assumptions will give to more such CEO, XX-Q. data the actual Saundra to relating important are risk please to independent other our a we undue data and and could market Form our cautioned factors estimates XX-K number With recently detailed and annual turn Also, by growth and size you made limitations, to discuss not report to weight and industry. over Pelletier. filed and our

Saundra Pelletier

$X.X Thank strong highlighted Amy. We of reporting today. are Today operating further the And another net expenses joining in reduced to increase of thank we QX for you, everyone results, in We XX% total by operations us driven U.S. narrowed sales. expect ongoing a X%. improved Phexxi quarter And you product by penetration we growth our by and operating our contraceptive loss XX%. from by market. beyond billion

a reminder, ovaries way. contraceptive not egg. product Phexxi approved our that impact the women does of are new controlled fertilized non-hormonal prevent Nor is For a only and product and Evofem an you woman's implantation it any those important FDA as does in of the that first innovative

CFO, ask growing With results. to and review the on I current will Jay Evofem financial women awareness access environment. the of the Jay? that, to contraception, sustainable the poised File Phexxi our to amongst about concerns is capitalize With

Jay File

exited quarter million of quarter Net the ex-factory driven Thank going you, GTN lower was $X expect about Saundra. better. net EVOGUARD for relative which of will first Total second by lower expenses was I'm product to trial QX. continue or driven $XX.X remain X% Today, costs completed results operating XXXX. XX% million. XXXX Phase to the to were level study. this of quarter XXXX on the and X in and decrease gross as sales the $X.X to XX% increased mainly reflects by costs, higher The R&D to second million And decreased sales. the to we focus This of participants

QX costs quarter completed to was down were were beyond. in marketing since should in to in costs last be patient and costs significantly expect come We up lower late QX, and $XXX,XXX the Selling visit lower $XXX,XXX the costs in R&D G&A legal July. fees. R&D third while due

operating to As of from and a revenue XX% loss a improved operations lower expenses, $XX.X result our higher million.

$XX to expect million in year. the range the half with building second product XXX% million, of to be represents continue will XXX% of net XXXX sales the We year-over-year. to momentum growth $XX in This

We in XXXX. better, be to million the $XX track lower half or will by We remain costs trending the of expect reduce net gross second in to year. XX% on

same the Our half XXXX. first versus total the of $XX.X operating were in period the of expenses year million lower

to later quarterly XXXX. breakeven still be cash the no on than expect Finally, end we of a flow basis,

cash unrestricted of we operations terminated million into that common August close net in million the million fund not line have proceeds of our received raised in in underwritten issued restricted warrants to X, of Through $X.X in credit capital. current from offering cash and $X expected $XX.X potential the $XX.X QX. quarter, the from main second and XXXX, At an of public equity million does we we were from we we Based offering. During sufficient operations, public our which exercise May. we believe million This QX, on cash. $XX.X include had non-dilutive

evaluating For commercial alternatives, an shareholder to partnerships. and U.S. we co-marketing end like are exploring and co-promotion value

XX with our required Capital continue days we to listing the term. the above We efforts Market bid $X as May regain closed requirements. by compliance minimum NASDAQ NASDAQ In trading for consecutive

milestone. is granted or to took at August price closing reverse of $X the XX our unexpected least request at panel step for second our of split, continued provided without able requiring on bid Ultimately, consecutive least evidence achievement the compliance XXnd. of disregarding a shares the stock trading panel the by of However, Evofem's Capital company Market, share this a per listing the NASDAQ days

Given current is the strong our especially a market billion And investment, $X.X with back contraceptive QX growth smart Evofem I we Saundra. that, solid it hope upside from our at support who in share opportunity see I'll to results, prevention, STI turn for the in believe investors ongoing price. the over and

Saundra Pelletier

Xst, impact business said. and our ability enhance we developments go XX that to deliver our what positive have will shareholder forward Since April announced on long-term Building Jay value. all favorably

Phase increase community. pregnancies The women presented and which We AMPOWER is of prevented Phexxi translating in was per resonating that important Phexxi of active data XX% prescription four the have uptake, trial, should into growth. sex clinical the with new published X most datasets and healthcare This alike. demonstrating to on these providers medical

a chart Phexxi to a spiked lifestyle came wall, It with People patient As had the to placing read informed every was on AXXX care. magazines contraceptive chart media. of coverage Phexxi including since CNN launched growth more utilization, and entertainment Phexxi News, well before developed should and assists branded still far more. an their partnered their shelf, and We contraceptive online deliver providers new developed and healthcare as like It Better methods providers methods in Magazine, on OB-GYN June, Phexxi. control as market. and prescription all organization, which features educational Media birth widely covering new of available counseling translating Evofem we many increase counseling. to dramatically assist Media in to outdated patient proactively centered replaces in NBC content

Moving four is life goods our Matter and shelf our protection forward leadership of at Board to A Directors. the allowed FDA The And through years. and to XXXX. of expected also extended Composition cost to Phexxi decrease team we up our new of Phexxi manufacturing partnership Phexxi’s XX%. patent strengthened covering was providing least

for continue with secure We to coverage Phexxi payers.

and from added to among increase is formulary is win this XX the of million to look Phexxi its largest largest nation participants. in one long-term with we template PBM's a forward Our prescriptions prescriptions This the cost to by Each our for save us operating with PBM. restrictions. This agreement upwards that remove was $X significant, delighted this Phexxi national contract expense. from Phexxi PBMs no is authorization prior to also costing of year we're $XX this prior expected authorizations to us and removing a process million

the on market wake of will continued XXXX that on This tailwind approved in and a since are Phexxi for and of to June to welcome you. that of of approved. catalyst The you increasing have who on focus responded we decision increasing Evofem consecutive increase a XX% consumers. have Roe their for you are ruling through media investors, XX. our of positive loss. growth. Our for than to currently a operating Supreme these this provided prescriptions we stock Phexxi And Phexxi look among net improved versus the well thank fill Many I your means are as being refill to tremendous this new you want the by Court on QX visibility claims has was accomplishments. more as while, the to I has claim support opportunity that for product sales Wade to biggest forward day, want as on quarter of was with able the created Every those prescription and impact to more company. those us agreement to rate women new been another The contraception continued and build

reflects recognition We Phexxi’s heightened with the This prescribers traction growth innovative growing of attributes are delivering and insurers. women among consistently directly and quarter-over-quarter.

FDA. insurers Based remain Jay and $XX The ACA Treasury the to We the of with revenue Last are on contraceptive capacity. to Health reproductive Labor cover achieve and all control following of of granted President counseling like U.S. access XXXX that at This women's including healthcare, our expect Services, million. the cost Human free all approved, guarantees released that the health the contraceptives on by indicators, guidance guidance strong million individuals. current birth contraceptives we to to $XX as or reproductive coverage quarter dependents in and track week, QX. covered ensuring Biden's another Departments encompasses order mentioned, preventive plans group no services, on trends cleared and individuals clarifying and Phexxi at for executive must and

with for what profitability prescription. them edits, more claim removal So money every ensure it of restrictions. women, Phexxi with goes team that no to previously costs. out to as mean women cost advance doing and were with of does means to these that means programs of It to copay plans increases covering that to sooner step is It and authorization Phexxi discussions guidelines access Evofem's this PBMs less at Evofem? denials, have prior means no renewed that our no market Phexxi access barriers, having the non-compliant that impermissible insurers such letters at and pocket

of As per we our The conservative, to million product who market Phexxi billion. at box. women potential is our of boxes year, my share market market in a XX.X of only If share market you $XXX looking the XX users it we're Phexxi a million Phexxi of reminder, addressable per to X% the women current and Evofem. net are of each the Every net represents of $XXX being slide, is Those one gross At United in in this total of States. be significant XX%, four QX get for WAC there XX.X net $X.X equals favorite. applicators, $XXX.XX sales. contraceptive million sales Phexxi estimated applying box X% are per

providers is reality month write a most six the that prescription. However,

is net women economics favorable. a are a we though business. equals sales. six approved market year, or also are million month Contraception profitable in with Especially prescription. even six for far the gross $XXX Phexxi XX%, equivalent. more to no get of company an X% boxes generic number So when with net to improves proprietary women share of product per know FDA competition when a And And beyond our each Phexxi getting

that Moving people often opportunity, our and significant chlamydia years. infection. market visit in reproductive had prevention the X Research announced woman found that upside Phase women lubricants our estimates current week, in that in our providing for million day replace is expand personal in infection is would CDC U.S., last this million opportunity of treatment the their with and Chlamydia the Yet million on of expect XXXX. are the don't prevent reported Phexxi one chlamydia sexually gonorrhea. we every and The which the for EVOGUARD causes data have of STI The study no year. study, and the We're women the symptoms. is given FDA at to all new XXXX. women use program users XX that people XX% of indicated risk. those There of shareholders top shareholders on leading October. study beyond the is occurred active most sexually respectively, contraceptive in Phase are XX% Infected all of know states track women emotionally product prophylactics is our seek people with bacterial no chlamydia for cases any we STI would is of active of additional Regardless and registrational of and This risk. in Almost are CDC United last women to The widens to an because significantly. lubricant enormous. and for choosing, to women. they approved the clinical infections. Americans are States and are two thirds U.S. risk frequently opportunity market for controlled daunting. here their market Success double approved financially of chlamydia on for has An in Monday unaware gonorrhea in still lubricant line it's the of these trial we infected infertility their report in the X.X X prevention of need and On Phexxi X patient gonorrhea STI at women in STIs. evaluating prevention our at

label. of XXXX. to prevention Phexxi’s applications women gonorrhea outcomes in in the first We seeking regulatory will be submit would add chlamydia us filings These to to expect to the positive enable half FDA and of sNDA

We and market. XXXX. indications, addressing approval receive out believe we not so billion that point the reflect have with for indications Phexxi new like current upside for could term we $X.X can designation Fast U.S. investor. we With does We incredible both the your valuation to not opportunity potential in FDA I'd It potential Track contraceptive we please count these does in in on our are the in to believe this an right hope that support. prevention. for questions. we opportunity near STI open the call factor the that operator, presents And

Operator

Instructions] And [Operator have question do coming we in now.

is Piper Sandler. one from David Amsellem, first The

David Amsellem

this Roe the But are but practitioners, but v. patients? in late, level and from first So, That's this I had you field just of hearing since of addressed what in of net, also Wade, for what interest it the gross number two, is, should one. number from is, Saundra. question have to, the environment not overturning the think I of so I joined about on terms you steady better, state I then -- just may And different and is, the year? I being like with which beyond always we contracting is and ask how feel course, the need with I question, this that the to but

Saundra Pelletier

I start, will to and will then Jay about I to talk net. So have gross

Court in you heightened there So the mean, here's expect, what would decision the a of on I hearing urgency we're since abortion. field. Supreme sense is as

entire providers meet our to with in more hearing the that know wanting and more wanting healthcare and to sales understand team interest Evofem from offerings are has. and We

being they a will choices talking are offer on also actually available up their to less depending about have having We lot HCPs, of might state, to that women. what end

from charts of of this choices, their you waist point, upon don't ceiling, things been when And women wall what choice for are staring for control that's know patient waiting educational David, and and nude the best in, rolling no that the oftentimes, you're them? a -- to if update there for your took what down birth and or really you're has one chart And more than chart. counseling on So the myriad is to is show ourselves. the and waiting frankly so at what come choices, out doctor were we years, at happened this I in these but you're proactively XX the room,

Officer to was are Isn't repeatedly a charts. been Commercial the the into and Chief have our their ineffective. that, So in saying busy it fact, In counsel they're field “Look, outdated these If day. better?” wants so anybody charts woman,

example, saying charts. in we calling reps we offices at or charts, eight eight that have they least we rooms, need have brought in constantly we have and two an As exam one calling us saying

much has in need their for start sex So was who that that just hormones product We've The we our access. know showed breastfeeding been writing XX% women I analysis because coming before. women to counseling maybe are available, some one sustainable might we're what now And is” they doctors impact that for that or are as of about a mind to the want of hearing ovaries, that understand have know are the lot prevented for anything switch Phexxi to an than I does active nervous, But based did weren't even Phexxi they're or for a counseling women are “You and who lever Phexxi has can't not be focus. saying the to heard patients, perhaps something physicians that per the negatively broaden things think course, much we should ones expanding on and use cancer not more woman's do time biggest who of as women, about this to there biggest on -- heard woman using want to to -- say, what of that that, the interesting is worried they're else. they people counseling become doctors, patients, pervasive but now We counsel that really more, pregnancy.

that, bittersweet. was mean, company. it us, run say this a would healthcare I of So kind on, come is Obviously, decision women's for I I tough.

that But very would you We increase tell I in expected Phexxi significant. been it interest has the though. for

decision what what final though might than that's that that hearing further on on the But people be so are, are we to of But themselves. I are it about hoping skeptical thing are a brace abortion. would some hearing. we're are, of people And just is themselves the be to where They're depending trepidations, states the representatives starting say lot where where already these go brace next. starting and doesn't

talk to GTN? want about You

Jay File

follow-up we asking maintain were it. range. on in your To as go still pleased We valid, very would obviously GTN always end so consistency at QX GTN Sure. it question, believed the XX% keep its see to on of that

reaffirming through to We anticipate year why possibility as Why our seeing our programs. through other then of during them quarter. but little the attributable to are obviously that the with is utilization significant is contract summarized PBM the a that reported goes not a see copay the less we is, little lower guidance largely that of you less end is start important of half on. XX%, come we releases press it have that some here. of those And that because is and new strong copay are the that programs. very the of than so on some And of attributable only wins year continuing do our saw you That to

sale our to net goes So have away Phexxi direct revenue that's chipping number of can start obviously that, to it every benefit as on anytime of a you forward. going

of through, of do XX% we that to and we to think XX% expect see And going is that ACA we -- how know when do the through next reality the at coming And costs. exempt significant of near I will are see at we distributor to stay just that, mix. are it never with XX%. associated well. in is of those be that do through, could there. timebeing going going do we have for distributor, we impact with ultimately point negotiate lieu negative But next and doing and is. on a always away. anticipate But always improvement full can down volume some go cost have impact the from But have costs guidance always the down next give Now, a as a year, and a GTN other coming XX% to in administrative time that year be to good over actuals years, we -- flow some increases, continued see then do in We'll we there's get bit future. We'll we private those mandate little few here we probably ACA, don't that's a updated get that always ultimately us headwind costs plans some think public, to to the few But as business. probably

Saundra Pelletier

David? Does that your address questions,

Operator

question Jen, All another right. Laidlaw and coming Company. Yale have do We from in

Yale Jen

for the afternoon, and questions. Good thanks taking

going review last that, have some quarter. great The quarter? -- questions. it's certainly then And follow-up first in I question quarter, last script the is numbers to you what's the Are a guys

Saundra Pelletier

and seen that you. a you XX% we what growth. tell Well, had We XX% have tell quarter-over-quarter, we can -- here's we have can

the example, the rolled after So spike an is drove Media AXXX a two that we for on things as just XX% demand call, the weeks. And done initial we increase. in seen of it shared out one have we when rollout, we've the

growth, lot seeing those and seen happened. Murphy, result to We And rollout of interviews. did just Annie that's whole ready series a with is a actually a that so the and a people what come lot of for been we we a of gotten seeing of have lot attention. as interviews media There's rollout media distributors getting are that wholesalers we have more

July also PBM restrictions. no was came this the with largest particularly So that day board Xst on

think actually as goes not but time next we're So continuing now feel we growth, much few momentum the just more see and I like growth over on really weeks. you'll

Yale Jen

increasing. brief And few -- is can sort roughly outcomes already month here month one a question revenue and indicate? kind that And of share more the of anticipate days. a for you and or growth the you've can Any colors seen that any probably trends you you third this quarter,

Jay File

I will that. take

Saundra Pelletier

Okay, okay.

Jay File

Yes.

in some of are you year. much to we kind what That still give the for too won't we reiterate might firmly to you sequential this XX means guidance as too give the obviously, on much I But forward growth quarter-over-quarter, XX So million holding guidance obviously, insight, obviously, just gave, million, gets we the it to guidance details. going there. for --

as large be that of building this of nicely are to was going on, heading are Second coming we the half. year. the half we far into believe the to year, PBM ACA the those getting the our just And of very going first mandate as stronger second be always of half both half on strong into falling year, knew win things and having headwinds place

look million to in the when year-end. growth, some the good we'll we've I million as and year, XX we half So to that already the quarter-over-quarter between XX get and would see second through shown fall of for continue first sequential

Yale Jen

second Maybe improvement, of reason year, that the regulation ACA you that would GTN GTN? half will mandated. on one more could impact this and Okay. see mentioned the change squeezing And question, do or over see small about be any changes even the be you would you the which

Jay File

need follow the week? Guidance Yes. year immediately. be to as interpreted we out, It -- in earlier January put X. I push can can You that very saw is where ACA. this just the basically about the last find implies release don't know, press that if recent was out, you final came two you

the roll start half the we goes the the need will improvement to second of of the So as year to those we And think question bit guys done that have blame program. them, out Coupled why seriously. oversight And copay say on. I’d will the in Saundra's they're payers were continued [indiscernible] we of key with fortunate… complaints, extremely see you to on from utilizations agencies will the there's of pursuit direct and And ultimately, current timing can't hearing think relentless members to as are and taking down them, comply PBMs. immediately. continued enforcement it the come continue committees to government I that's administration this a it But over

Saundra Pelletier

these a and thing to that side offices huge the push talking one Well, make they're of heard examples sure from the of have specific to from just women. stepping that didn't of women Democratic getting people that lot Yale leaning know asking past, up in they the of we in and is for a now and to reaching and these are senators although there add Congress us are we specifics, is for all to have want consistently been that certainly out And denied. offices

being as seen and can halo standing be effect advocating will they they of up and that that ones hope women. reach out directly the the for for So are

what's we So, been very and i.e., occurring. refreshing And have action have but sooner, seen that we of serious it's the enforcement are kind seeing optimistic. deliberate happened action, should is

to get contraception. women So access abortion, readily they at are denied being more and safe get will least when more access to

Operator

Stifel. Annabel next Samimy Our from coming question of is

Stacy Lee

Annabel. quarter. for Stacy this Congrats really great a calling in on Hi, is

been repealed further protective it that's as for protect is prescription be of is STI Roe Just any And occurred really was to questions see it the remain the visit you of EVOGUARD last addition? better Can it on last having Wade product? and the secondly, give EVOXXX an the us how iteration end. own will helping around fulfillment? you to in the some contraception, a to latest and would treat Is with it, partnership to enhancer profile trial. there know, more than how to versus focus being that excited the need is thought contraception. I successful? with Or development its profile two increased the we're light In our metrics VitaCare

Saundra Pelletier

the start for the Jay will want to thanks jump question. I Yes, in you second and one. for

Jay File

Yes, jump on VitaCare. I'll in

was the for little them. pilot a from get it did go. the quarterly And right do a style specifics just So we bit activities, rollout successful with of extremely

very platform happy fairly new with are that. out. a We going complex to the Obviously, process see

still service really white-glove, on in from to multiple Xst. integrating come what is sources from the is was make And integrated, out were that field sure our program and effective kinks process, been from it well that the in as starting patient entire really and -- come term extremely August we to it's multiple already to is. on reminder, office, way all rolled that and reps, we're board pilot process. process itself and this we've the other through ensuring the really, sales worked all out. and experiences doctors' the they So get And through but follows patients is favorable. refills actually across exits Feedback a the truly any And the have wanted doesn't this vendors. their that that that, fully Subsequent a seeing we're beyond and timely experience the this a with basis, received fully them that

fall results. we're out And from been and it’s truly much extremely results. to So on when us the about for porthole QX insight Xst, rolled August one-stop excited launch to us. back initial for really And have more for this patients shopping we sure, definitely how on a as to talk we'll is I the our initial think

Saundra Pelletier

with on the Katherine, there add is know, the Commercial Atkinson to fully And anything is you want line. to Katherine just also Officer Chief you VitaCare our color us situation?

Katherine Atkinson

Yes, we've seen some great success.

approved we've XX had about and We’ve out. Of field work go August rolled many, all So which were the slowly beta had tested said, remainder. it to kind came on as of the it rolled prescriptions continues We out VitaCare in in. the to Jay and it we Xst. XX% that on already already

really we're about so it. excited And

ones and that So quarter previous we'll the programs to in not coming came have below for even this and in. XX% more finished our point up were really after with first we're far we that But color those you. great performance

already numbers. So really the bat great off

Saundra Pelletier

your make indication. want then And question. And EVOGUARD sure I just question want to regarding the STI I that to the and address

can not label think the to So you just product? a expanding you we again? want it -- the will know So separate whether as frame advantageous or as being be

Stacy Lee

correct. that's Yes,

Saundra Pelletier

Okay.

So one thing.

works asset. where CEO because I tanks, we let something of that this my and infection. the women's I be introduce road kinds call, pregnancy or you to product? would a pregnant sexual that you would hormones at activity After and that that when we NDA. which this around people work were ability from say no your a don't protect we're to different spending fabulous even diligence So product for submission products are couple as at journal. a your mean nirvana. you XX% day, recognizing, same I women, systemic a expanding leaders, in about life, cost. is used product, most erode they looking as was as you can What years, by hormonal properties, look have these And it us and allow us, would entire vaginal the just you that side in sex may most no is a get say women a to I this generics will to company time the prevent without modulator. getting thought get to The standpoint. would cost from with and payers, do have all chlamydia that think when that negatively gonorrhea. that me all down it and a will far of label you a certainly say a But have have we intuitively understanding for you importantly, sex talk understand to was no product categories, in product they not And a I've life look understand global it have you men wouldn't market timing it. ovaries transmitted women on is used was to pleasure and remember influencers, side the and And things. come done be not Women you pH to but is incurred from with intuitively tell and you that in that the attracted if better or and impacting now would sexually short the may me-too that had a opportunity how crowded separate demand, actually sNDA my whole important that years. the from and Well, we that our Phexxi. that would let's of you and suffer something if course, were with it. Doctors company, publication amazing we the but condoms have been health my the at something has diligence of have every of of providers consistently really will at looking financial concluded answer able in XX% be have Phexxi. only where it, when brand we When effects, the could is that know needed And the for that better financial those lubricating is it we on satisfaction we Where effects, product as be cost, XXX shareholders of to to with going will a there positive prevent And women, to that

easy And about really so it's use, it's feel and and simple to women it. good

to we and this we good opportunity all road. is the are is, Because so what we things years we want didn't want down a after significant. so relaunch infertility. that though very of the chlamydia to, submission is with be whether already even was of we these at life, trifecta patch, this might sort the of a say IUD, they their million down And health I women's that And being when even to in And to But comment NDA is, that X wonderful I this so pervasive, short young ability chlamydia do that they're is road. start to get now cases. shamefully of decide label would recognize on admit the to feel maybe that, for the thinking have you is market a when now, whole expanding road, XX five answer I my want or it talk may And as feel pregnant tell you six down said, or an reasons risk. pill, the I one women, about or to top final we still you're --

pregnant, pregnant, not ability your and So to product also use if a you're get would Phexxi? like about you're yourself you protecting worried why getting from

Operator

from question H.C. is Ram coming of next Wainwright. Selvaraju Your

Ram Selvaraju

quick Thanks three questions, very ones. relatively for taking much my just

ruling? I you're hormonal the categories to was that of Court assuming for readouts was Supreme be commercial specific have about you value on, in of if development you of I control? Phexxi, indications, cancer forms the any go lead all, population was comment Thanks. could all And them in are returning the for would an women involve sort context was you trajectory of the of business have the trends that thoughts emerging the kind particularly whether and of wondering if how regarding you birth any ineligible of lastly, in at who particularly to commercial optimizing in STI the then that prevention, strategically activity, of updated wondering private in mooted U.S. non-reimbursed updated opportunity? drug on would pay, of demand in positive would wake of concept Secondly, Phexxi's take or I on treatment that the First undergoing wondering seeing if sort early

Saundra Pelletier

right. expand with backwards, is, is definitely label the much saying of Thank add you, provide I'm Ram, that we meaning prevention And start to I'm why and population. if to the the And like wider when to want to last all on that's gonorrhea, your I’d definitely. short we much chlamydia very to the one, broader STI for answer a opportunities. access going questions. start much

co-promotion be that Jay’s that beyond looking partners. as expand certainly OB-GYNs yes, We from believe -- it you frankly. think will we at do co-marketing are and we so And comments, heard that we the top will but prescribers,

for very an strategic tell trying we partner to another finding So opportunity is a footprint. wise looking to and a additional about that And has story. that are be

has doing tell we when now we STI, focused because on that with versus constant what's Business people I that Roe you get you who've of right these our fascinating time Wade, we is will waited little we that are with could talk is now. XXX% actively partners. development, us while, business been multiple, that I said we're the that trepidatious the tomorrow. can know, But the Head Development, a right those are agreement have So we Yes, partnerships us and distribution strategic so continuous. full partnerships about a so been contacting of for and for get a

going there's to align messaging, to with reach. question… expand if U.S. bring the So the your the our Then we to are are branding the somebody and in but we And to look of capital. second partner. controlling appropriate non-dilutive our Still outside to continuing see in an efforts U.S. obviously

Jay File

NCODA.

Saundra Pelletier

NCODA. Yes,

we become can to it's XXX,XXX Head we I if is, with oncologists out that one, that as open can continuing NCODA, time patients? from do Roe his certainly that that, What women their cancer you, are. who the spent in with that see the has of we important vulnerable other you He's are to physician extraordinary So, for us one versus been is have product Phexxi you passes, are up to if and don't know see patients the grow. there our is estrogen is one of identify but the And think eyes to that they feedback What's state. a they their want patients the far regardless also don't has that things obvious career though which and oftentimes carveouts during the from oncology who and we cancer what relationship copper Wade the these does organization identify, a Sales, are way. have. that pregnant sales cancers cancer helped tell of even by happening they have will align way gentleman challenging see that is would to have is choice. only our but IUD type, want in to What treatment, tried patients effects to a is a are side there of that we too

asked to do to conversations been all hospitals the provide elevate to we of and So continue have products to seeing continuously being kinds and to go Grand Rounds escalate conversation.

have to not way segment would say So a specific growing, had I we actually that that population. it is

of they part to doctors, are we're talking bigger when However, practices.

are by to and making are those we those a organizations, to so are survivors that our centers. making whom And some hospitals in talk go effort always way, those themselves, And we our business. that's of boosting sales deliberate sure the cancer think clinics to

Chief address you? The first or File to know question, File, our Jay don't Officer I to if Jay Commercial like it. do want

Jay File

do okay, no, -- Yes, we perfect. Katherine. ahead, Go

Katherine Atkinson

being, think, women. actually small of again, some are way, something in we this one thing helps spite private think mention, I we help of this Well, could are whether that and is, these moving I that could proactive payers in doing

going few card the rolling cash out program a have in we next weeks. to we're that So be

do to we're even increase immediately, if moving access going what So payers to aren't can. we

Saundra Pelletier

address questions? that does Ram, your

Ram Selvaraju

who also folks doing clarify, interest very was those Supreme in was since just But are that think an you're pocket, of pay of seeing not? Yes, to out of asking to I or Court if sort about, helpful. the that increased ruling I prepared level

Jay File

Yes.

think two also And self-pay I think on we is either truly But just think, are on of the an going that obviously, that, the still Phexxi to anecdotally, come category starting ultimately about always in. to say data. you're that come into to speaking, as to Roe because decision timing behind get get expand will clarity of I level, script to traditionally, it's that out. card rolled that part, it Wade implement of we'll that our weeks we kind if see very issue we in is It coming to was prescriptions just I that cash out advance number majority we recently degree. we referring great is had better that And of v. to. through, not trended think that -- Katherine is is actually on see sales. significant there, which are I out, coming our program rolled one did through. that them a is But I being the why

support a they'll insurance and/or their have assistance payer of that or right, program, sort state they've means. program through governmental federal Some got own coverage

to follow-up something see that on we've much and with I truly see QX, timed someone We have So potentially is put truly time that But have on we'll is if rebate definitely -- straight a on we'll better paying either cash of and that a our who visibility trending assist in them. be right is there. uptake I steps to we'll at card. they'll think out think that pocket, doesn't true on in something

Operator

for That's today. I'll time the to turn all closing Saundra over have that the for we call back remarks. Pelletier

Saundra Pelletier

Thank you.

in dollar We continue sales multibillion product to Phexxi grow contraceptive U.S. quarter-over-quarter the net market.

XXXX. track We are to guidance meet for our on

access U.S. government the access. zero Supreme on pregnancies. are ruling Wade versus The guidelines unintended increasingly at women protect to with June, cost to contraceptive Court should With Phexxi motivated women in from the catalyze Roe no from themselves on to recent to barriers access

contraception, execution for hormone and gonorrhea Additionally, than the closing, free want remain we deliver to STIs. in shareholder there value. stage focused program of is ever, time prevention The In is I long-term for reiterate that of developing our from women. prevention business to Phexxi Phexxi of upside now. for chlamydia The on is strategies potential need late our and greater for significant both

have about we with on We are to are very our And us. happy very, journey future. excited you this

in but of gray very share were our As but started in forthcoming we such a to grow, in XX deliver obvious not value October that for were business product a since to this able wasn't and that delivering it fluff. of milestones you deliver on attributes to the I that time These readout to execute, that we intentional Those prove have when this STI inflection share are it been that our only drivers whole deliberate, innovation, look return, April, an There in continue shareholder XX. And to organizations that to today, deserves significant. not our makes study this I value that's is there. we the very we're lot continuing announcements investment. to call, are said deliver when on

of I your to you and been the you welcome for day. want your for again, people to while really So a that to that a us and ongoing rest thank new, great want love I'd I all are of Have support. have with thank

Operator

and Ladies thank us. you for gentlemen, joining

You may now disconnect.

Evofem Biosciences (EVFM) 5 Aug 222022 Q2 Earnings call transcript